Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

K.C. Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-03-03

Lack of Assurance of Sterility

K.C. Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-03-03

Lack of Assurance of Sterility

Owen Biosciences Inc.

US Class II Ongoing · initiated 2026-03-03

Chemical contamination: Presence of benzene

Owen Biosciences Inc.

US Class II Ongoing · initiated 2026-03-03

Chemical contamination: Presence of benzene

Owen Biosciences Inc.

US Class II Ongoing · initiated 2026-03-03

Chemical contamination: Presence of benzene

Owen Biosciences Inc.

US Class II Ongoing · initiated 2026-03-03

Chemical contamination: Presence of benzene

STRIDES PHARMA INC

US Class II Ongoing · initiated 2026-03-02

Presence of foreign substance: the firm received complaints for a gel-like mass and black particles in the product.

Cardinal Health 200, LLC

US Class I Ongoing · initiated 2026-03-02

Non-Sterility: microbial contamination identified as Paenibacillus phoenicis

New Life Pharma LLC

US Class II Ongoing · initiated 2026-02-26

Lack of Assurance of Sterility

New Life Pharma LLC

US Class II Ongoing · initiated 2026-02-26

Lack of Assurance of Sterility

New Life Pharma LLC

US Class II Ongoing · initiated 2026-02-26

Lack of Assurance of Sterility

New Life Pharma LLC

US Class II Ongoing · initiated 2026-02-26

Lack of Assurance of Sterility

MACLEODS PHARMA USA, INC

US Class II Ongoing · initiated 2026-02-26

Subpotent Drug

Champignons et Adaptogènes

Canada Type III Ongoing · initiated 2026-02-26

Dosage. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.Conta…

MYLAN PHARMACEUTICALS INC

US Class II Ongoing · initiated 2026-02-24

Failed Dissolution Specifications

Radnostix

US Class III Ongoing · initiated 2026-02-19

Failed Tablet/Capsule Specifications

Cipla USA, Inc.

US Class III Ongoing · initiated 2026-02-18

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection te…

HTO Nevada Inc. dba Kirkman

US Class II Ongoing · initiated 2026-02-18

Stability Data Does Not Support Expiry Date.

HTO Nevada Inc. dba Kirkman

US Class II Ongoing · initiated 2026-02-18

Stability Data Does Not Support Expiry Date.

HTO Nevada Inc. dba Kirkman

US Class II Ongoing · initiated 2026-02-18

Stability Data Does Not Support Expiry Date.

Cipla USA, Inc.

US Class III Ongoing · initiated 2026-02-18

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection te…

CEFAZOLIN FOR INJECTION USP 10 G / VIAL

Canada Type I Ongoing · initiated 2026-02-18

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

Teva-Indomethacin

Canada Type II Ongoing · initiated 2026-02-18

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

The Harvard Drug Group LLC

US Class II Ongoing · initiated 2026-02-17

Defective container; inadequately sealed blister packaging.

APO-CANDESARTAN

Canada Type II Ongoing · initiated 2026-02-16

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…